Market Snapshot

BSE Sensex: 78185.13 0.28%
BSE 500: 35197.28 0.70%
BSE 200: 10945.72 0.64%
BSE 100: 25062.73 0.35%
BSE MidCap: 46240.08 0.98%
BSE SmallCap: 55143.5 1.48%
BSE BANKEX: 57155.45 0.73%
BSE IT: 43358.08 -0.29%
Nifty 50: 23717.6 0.43%
Nifty 500: 22326.65 0.46%
Nifty 200: 13385.25 0.40%
Nifty 100: 24487.3 0.34%
Nifty Midcap 100: 56760.9 0.70%
Nifty Small 100: 18569.85 0.78%
Nifty IT: 43360.3 -0.72%
Nifty PSU Bank: 6404.35 0.79%

News:

Shakti Pumps gains as board OK...
Royal Orchid gains on inking n...
Vantage Knowledge Academy hits...
Alkem Labs gains after inking ...
Piramal Pharma gains on appoin...

Bliss GVS Pharma Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

Invest

07 Jan 2025 | 12:29 PM

175.30

8.47 (5.08%)

Add to Watchlist

This awesome feature is still in our labs.
Set Alert

This awesome feature is still in our labs.

Outperforms Index

38.74%

Return (1Y)

Beaten Nifty 50 by 28.97%
More Volatile

3.3%

Standard Deviation (1Y)

Higher than Nifty 50 by 2.41%
Consistent Performer

7/12

Months

beaten Nifty 50
AxisDirect View

No View

52 Week High-Low

186

News & Announcements

Bliss GVS Pharma allots 34,250 equity shares under ESOP
32 days ago

Bliss GVS Pharma allots 34,250 equity shares under ESOP

06 - Dec - 2024 12:00 AM | 32 days ago

Bliss GVS Pharma has allotted 34,250 equity shares under ESOP on 06 December 2024. With this allotment, the paid up equity share capital has increased to 10,53,66,272 equity shares of Re. 1/- each aggregating Rs. 10,53,66,272/-.
Powered by Capital Market - Live News
Bliss GVS Pharma soars after manufacturing units get GMP certificate from Romania medical authority
43 days ago

Bliss GVS Pharma soars after manufacturing units get GMP certificate from Romania medical authority

25 - Nov - 2024 12:00 AM | 43 days ago

In a regulatory filing made on Saturday, the company informed that its manufacturing facilities located at Aliyali Village and Vevoor Village in Palghar district of Maharashtra has received a Certificate of GMP (good manufacturing practice) Compliance from the National Agency for Medicines and Medical Devices of Romania (NAMMDR).
The compliance certificate has been granted following an EU GMP inspection that took place on 30th November and 1st December 2023 at the said facilities.
Bliss develops and manufactures pharmaceutical formulations mainly for sale in Africa. The company sells formulations in the form of suppositories, pessaries, capsules, tablets, and syrups. It manufactures more than 250 branded formulations in the anti-malarial, anti-fungal, anti-bacterial, anti-biotic, anti-inflammatory, contraceptive, and anti-diabetic segments. Bliss also contract-manufactures suppositories and pessaries for Sun Pharma and Mankind.
The company's consolidated net profit declined 42.66% to Rs 24.26 crore despite a 2.74% rise in net sales to Rs 217.68 crore in Q2 FY25 as compared with Q2 FY24.
Powered by Capital Market - Live News
Bliss GVS Pharma's manufacturing facilities complete EU GMP inspection
45 days ago

Bliss GVS Pharma's manufacturing facilities complete EU GMP inspection

23 - Nov - 2024 12:00 AM | 45 days ago

Bliss GVS Pharma announced that the company's manufacturing facility situated at Plot No. 11, Dewan Udyog Nagar, Aliyali Village, Palghar, 401404, India and Survey No. 43-44, Vevoor Village, 401404, India, has successfully received a Certificate of GMP (Good Manufacturing Practice) Compliance from the National Agency for Medicines and Medical Devices of Romania (NAMMDR) following an EU GMP inspection that took place on 30 November and 1 December 2023.
Powered by Capital Market - Live News
Bliss GVS Pharma consolidated net profit declines 42.66% in the September 2024 quarter
74 days ago

Bliss GVS Pharma consolidated net profit declines 42.66% in the September 2024 quarter

25 - Oct - 2024 12:00 AM | 74 days ago

Net profit of Bliss GVS Pharma declined 42.66% to Rs 24.26 crore in the quarter ended September 2024 as against Rs 42.31 crore during the previous quarter ended September 2023. Sales rose 2.74% to Rs 217.68 crore in the quarter ended September 2024 as against Rs 211.88 crore during the previous quarter ended September 2023.
Particulars Quarter Ended
Sep. 2024 Sep. 2023 % Var.
Sales 217.68 211.88 3
OPM % 19.05 25.66 -
PBDT 42.69 65.52 -35
PBT 35.71 59.13 -40
NP 24.26 42.31 -43
Powered by Capital Market - Live News

Price vs Volume

Stock Trivia

Bliss GVS Pharma Ltd is trading very close to its 52 Week High
FII shareholding in Bliss GVS Pharma Ltd has decreased by -8.42% since past 3 Months
MF shareholding in Bliss GVS Pharma Ltd has increased by 100% since past 3 Months
FII shareholding in Bliss GVS Pharma Ltd has decreased by -25.64% since past 1 Year

Peer Comparison on Risk - Return

Thanks for Liking, Please spread your love by sharing...

Particulars	Quarter Ended
	Sep. 2024	Sep. 2023	% Var.
Sales	217.68	211.88	3
OPM %	19.05	25.66	-
PBDT	42.69	65.52	-35
PBT	35.71	59.13	-40
NP	24.26	42.31	-43

General Notifications

My Notifications

Research Notifications

Bliss GVS Pharma Ltd Share Price – NSE / BSE Pharmaceuticals, Small Cap

175.30 8.47 (5.08%)

News & Announcements

Price vs Volume

Stock Trivia

Bliss GVS Pharma Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

175.30

8.47 (5.08%)